1Spratt JS, Adcock RA, Muscovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy [ J]. Cancer Res, 1980, 40 (2) : 256 -260.
2Fujimoto S, Takahashi M, Mutou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery[ J]. Cancer, 1997,79 (5) :884 - 891.
3Alberts DS, Lui PY, Hannigan EV,et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage Ⅲ ovarian cancer[J]. N Engl J Med, 1996,335(26) :1950 - 1955.
4Westermann AM, Grosen EA, Katschinski DM, et al. A pilot study of whol body hyperthermia and carboplatin in platinum-resistant ovarian cancer[ J]. Eur J cancer, 2001,37 : 1111 - 1117.
5van der Vange N, van Goethem AR,Zoetmulder FAN, et al. Extensive cytoreductiv surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent overian cancer: a feasibility pilot [ J ] . European journal of surgical oncology, 2000,26 : 663 - 668.
6Panteix G, Beaujard A, Garbit F, et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy [ J ]. Anticancer Research, 2002, 22 : 1329 - 1336.
